Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cervical Cancer: An update on the guidelines for screening Shikha Bose M.D. Prof. of Pathology Cedars Sinai Medical Center & David Geffen School of Medicine, UCLA Global Cancer Congress Sept. 20, 2014 Worldwide Cervical cancer Cervical cancer is a considerable problem 555,100 new cases 80% of these will be in low/middle income countries Third leading cause of cancer death in women 309,800 deaths annually 73,000 deaths in India (1/4) Cervical cancer incidence rates Global Cancer facts & Figures 2007, ACS HPV & Cervical CA HPV: Cause of Cervical CA HPV is a 55 nm non-enveloped double stranded circular DNA virus belonging to the Papillomaviridae family HPV cause papillomas Infects keratinocytes of Skin: hands and feet Mucosa throat genital area. HPV Harald zur Hausen - 2008 Nobel Prize for Medicine Was first discovered in the 1950s Stefania Ginsburg-Jablonska, Polish dermatologist, Univ. of Warsaw first discovered the association between HPV & skin cancer in 1972 Harald zur Hausen, a German scientist and virologist was the first to show that HPV causes Cervical Ca and identified HPV16 and HPV18 as the responsible strains. Anogenital HPV Most common STD (6.2 million new infections/yr in US) Warts present in 1% of sexually active people Subclinical infection >15% 1 in 2 will acquire genital HPV in their lifetime Worldwide age standardized prevalence of current HPV infection: 10.5% Varies between different regions: 1.4% (Spain) to 25% (Nigeria) HPV >100 types; 40 infect anogenital mucosa Low risk (LR)- HPV 6, 11 Condyloma acuminata (~ 500,000/yr) Juvenile respiratory papillomatosis Rare progression to cancer High risk (HR) – at least 15 known HPV 16, 18 – Commonly associated with cancer HPV and Cancer Cancer Type Annual Incidence/death (US)* HPV associated Cervical Vulvar 11,070/3,870 3,870/870 ≥95% 50% Anal Penile Oral & Oropharyngeal Esophageal 5,070/680 1,250/290 35,310/7,590 70-90% ~50% ~20-30% 16,470/14,280 ~22% *Estimated numbers for 2008 per NCI/ACS Origin of cervical cancer At the squamocolumnar junction Natural history of HPV infection Moscicki et al. Updating the Natural History of Human Papillomavirus and Anogenital Cancers. Vaccine Volume 30, Supplement 5 2012 F24 - F33. http://dx.doi.org/10.1016/j.vaccine.2012.05.089 HR HPV genotypes & Cervical CA HPV 16 – 50-60% of HPV 18 – 10-20% HPV 31, 45 – 10% Remaining 11 subtypes – 10% MOST infections are subclinical MINORITY produce SIL Small fraction of SIL lead to CA Natural history of CIN and Cervical Ca Viral Persistence HPV Infection CIN 1 Normal Cervix CA CIN 2 CIN 3 15 30 45 CERVICAL CANCER SCREENING The Papanicolaou (Pap) Test George Papanicolaou First announced the test in 1928 at a conference in Michigan. 1943 published “Diagnosis of Uterine Cancer by the Vaginal Smear” Best screening tool introduced for any cancer The Pap Test The Pap test, when combined with a regular screening program & appropriate follow-up, can reduce cervical cancer deaths by up to 80%. In the US of women with invasive cervical cancer: >50% have never had a Pap smear 10-20% have not had a Pap smear in the preceding 5 yrs 25% had an abnormal Pap smear, but did not get appropriate follow-up (woman did not return for care, or clinician did not perform recommended tests or treatment) The Pap Test: Limitations Good quality cytology-based screening programs require highly trained personnel, specialized equipment and screening at regular intervals Low sensitivity 50-60% (Specificity – 95%) • High false negative associated with • patient compliance • sample collection • subjective assessments Limitations of the Pap Test Good quality cytology-based screening programs require highly trained personnel and specialized equipment Low sensitivity 50-60% (Specificity – 95%) • High false negative • Increased liability • Requires screening at regular intervals Subjective assessments Newer modalities for Screening Liquid based cytology Computer - assisted screening Adjunctive molecular testing Liquid based Pap Test Currently ThinPrep© (Hologic, Marlborough, MA) and SurePath© (Becton‐ Dickinson/TriPath, Burlington, NC) are the predominant LB Pap test types used in the US. Provide a more representative sampling Decrease pre‐analytic problems: transfer of sample, excess blood/inflammation, and air‐drying. Allows additional tests for HPV, STI (Chlamydia, Gonorrhea and Trichomonads) from the same vial. Allowed the incorporation of computer imaging technology. Meta‐analyses do not indicate an overall increase in HSIL detection. Arbyn M, Bergeron C, Klinkhamer P et al. Obstet Gynecol 111:167, 2008 Computer imaging technology Two FDAs approved devices to assist in cervical cytology screening: The B.D. FocalPoint™ Slide Profiler Intelligent Pap Imaging™ system incorporates initial computer evaluation followed by manual rescreening of the most likely abnormal cases; the least abnormal cases require no review. The Hologic ThinPrep™ Imaging System involves automated pre‐screening and presentation of digitized images of the most abnormal 22 fields of view (FOV) to a reviewer, thus allowing a dual review: one full review from the ThinPrep Imager and another from an experienced cytotechnologist HPV testing Advantages: Highly reproducible Easily monitored Objective outcome 1999: FDA approved HPV testing for ASC-US Paps 2003: FDA approved for primary screening in women >30yrs Testing for low-risk HPV types has NO role in routine cervical cancer screening or for the evaluation of women with abnormal cervical cytology. The sensitivity of HPV testing is not 100%. A subset of carcinomas, both squamous and glandular, and other tumor types may not be detected by HPV testing. FDA approved HPV assays Hybrid Capture 2 Cobas HPV test (Digene Corporation / Qiagen group) (Roche Molecular Systems, Inc) 13 14 Same as Cervista except 66 Pooled: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 HPV16 HPV18 Invader technology In situ Hybridization Real time PCR Absent Present Absent Present Absent Present (β globin) Cervista (Hologic Inc.) HRHPV types 14 Probes A5/6 - 51,56,66 A7-18,39,45,59,68 A9 16,31,33,35,52,58 Test type Cross reactivity Internal control Summary of Screening Recommendations Population (age in yrs) Recommended screening method <21 No screening 21-29 Cytology x 3 yrs Management of screening results Comments HPV testing should not be used for screening or ASCUS triage ASCUS+ HPV+ ≥ LSIL Colpo CytologyASCUS+ HPV- Rescreen x 3 yrs HPV testing should not be used for screening but is used for ASCUS triage The American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: Screening for Cervical Cancer. November, 2012 Summary of Screening Recommendations Population (age in yrs) Recommended screening method Management of screening results Comments 30-65 Cytology + HPV (Co-test) x 5 yrs (preferred) ASCUS+ HPV+/≥ LSIL: Colpo Cytology- HPV+ HPV testing is done with the Pap test (Co-test) and is not recommended alone for most clinical settings 1. Co-test x 12 mo 2. HPV16 or HPV16/18 test Pos: Colpo Neg: Co-test in 12 mo Cytology- HPV-/ASCUS+HPV-: Rescreen x 5 yrs Cytology x 3 yrs (acceptable) ASCUS+ HPV+/≥ LSIL : Colpo Cytology-/ASCUS+ HPV-: Rescreen x 3 yrs Summary of Screening Recommendations Population (age in yrs) Recommended Management of screening method screening results Comments >65 No screening ≥ CIN2: routine screening x 20 yrs After hysterectomy No screening No cervix & no history of ≥ CIN2 past 20 yrs or Cervical ca HPV vaccinated Age specific recommendations (same as unvaccinated) The American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: Screening for Cervical Cancer. November, 2012 Co-testing: HPV+Pap test Sensitivity : • of HPV - 95% v. Pap - 55% • of HPV + cytology - 100% • referral rate - 7.9% Specificity: • of HPV 94% v. Pap - 97% Cumulative incidence of CIN 3+ when baseline Pap- HPV- : • 0.047% at 3 years • 0.16% at 5 years Katki HA, et al.: Lancet Oncol 12 (7): 663-72, 2011 Primary Cervical Ca Screening with HPV DNA Test FDA approved in 2014 Roche Cobas HPV Test Thin Prep Pap Test PreserveCyt Solution Endocervical brush/spatula Roche Cobas HPV Test Originally FDA approval in 2011 for Co-test and Reflex test pcr-based target DNA amplification and hybridization for detection of 14 HR HPV (HPV 16, HPV18 and 12 other HR HPV) in a single reaction FDA APPROVAL DOES NOT CHANGE CURRENT PRACTICE GUIDLINES HPV for primary screening Meta analysis of 4 European randomised trials comparing HPVbased with cytology-based Cx Ca screening (Swedescreen, POBASCAM, ARTISTIC & NTCC10) of >175 000 women HPV-based screening resulted in: 60–70% reduction in invasive Cx Ca incidence significant decreased incidence of invasive Cx Ca on longer follow-up observed cumulative incidence of invasive cervical cancer was lower 5·5 years after a negative HPV test than 3·5 years after a negative cytology test, indicating that 5-year screen intervals with HPV-based testing are safer than 3-year intervals with conventional cytology enhanced detection of CIN2/3 in screened women, therefore enabling early treatment and reduction of invasive cervical cancer risk ATHENA trial Prospective study of 40,901 women aged 25 years and older who underwent routine cervical exams Colposcopy and cervical tissue biopsy was performed on women with: positive Pap test positive HPV test subset with negative Pap and HPV tests (~900 women). Used to calculate verification biased adjustment (VBA) All biopsy results were compared with the Pap and cobas HPV Test results. 3 years of follow-up Provisional proposal for follow up Cobas HPV test HPV - Follow up x 3 yrs 12 HR HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 HPV 16/18+ 12 HR HPV + Pap Test Normal Follow up x 12 mos HPV 16 HPV 18 Colposcopy Abnormal ≥ASC Colposcopy